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 Summary
	 Background:  The	aim	of	the	study	was	to	determine	the	effectiveness	of	mammotome	biopsy	(MB)	in	detecting	
preclinical	breast	pathologies.	
 Material/Methods:  The	material	consisted	of	847	women,	of	whom,	based	on	mammography	and	ultrasound,	349	patients	
were	 referred	 to	have	stereotactic	mammotome	biopsy	 (SMB)	guided	by	digital	mammography	and	
498	women	were	subjected	to	hand-held	mammotome	biopsy	(HHMB)	guided	by	US.	
	 Results:  Ultimately,	MB	was	done	 in	 819	women.	 In	 all	 cases	where	breast	 carcinoma	or	 atypical	 ductal	
hyperplasia	(ADH)	were	detected,	the	patients	were	operated	on	and	postoperative	histopathology	
was	 treated	 as	 the	 reference	 for	 post-biopsy	 histopathology.	 Patients	 in	 whom	 post-MB	
histopathology	detected	benign	lesions	were	subjected	to	a	strict	long-term	follow-up	using	imaging	
studies.	Ultimately,	 thanks	 to	MB,	 94	 cases	 of	 breast	 cancer	 (12%)	were	detected	 as	well	 as	 725	
(88%)	cases	of	benign	lesions,	which	corresponds	to	a	sensitivity	of	98.9%	and	100%	specificity.
	 Conclusions:  MB	is	an	alternative	to	surgical	biopsy	in	differentiating	preclinical	breast	lesions.	It	is	associated	
with	a	minimal	risk	of	complications	and	may	be	successfully	performed	in	an	outpatient	setting.
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Background
The	 incidence	 and	 mortality	 rates	 of	 breast	 cancer	 are	
on	 the	 steady	 and	 fast	 increase	 in	 Poland.	The	 incidence	
coefficients	 increased	 from	 14.6%	 in	 1963	 (the	 standard-
ized	 incidence	per	100,000	 inhabitants)	 to	35.3	%	 in	1995;	
in	the	same	period,	mortality	increased	from	9.3	to	16.3%.	
Concurrently,	 in	 2000,	 the	 5-year	 relative	 survival	 rate	
for	the	entire	country	was	below	50%.	In	countries	where	
effective	systems	of	early	breast	cancer	detection have	been	
introduced,	 the	 rates	 of	 5-year	 survival	 range	 from	72.5%	
to	78.9%	(Europe	and	the	US,	respectively)	[1,	2].
The	notion	of	“early	detection”	encompasses	both	the	detec-
tion	 of	 tumors	 in	 their	 earliest	 stages	 (preinvasive	 carci-
noma)	 and	 as	 early	 as	 possible	 detection	 of	 all	malignan-
cies,	what	is	understood	as	the	body	of	activities	aiming	at	
detecting	a	neoplastic	lesion	(regardless	of	its	stage)	earlier	
than	it	would	be	revealed	without	such	activities.	The	diffi-
culty	lies	in	pinpointing	the	presence	of	tumors	when	they	
are	in	the	above-described	early	stage.	It	is	a	difficult	task,	
as	 they	 are	 usually	 less	 than	 1	 cm	 in	 size,	 non-palpable,	
and	may	 be	 detected	 only	 by	 diagnostic	 imaging.	On	 the	
other	hand,	 establishing	 the	 diagnosis	 of	 preinvasive	 car-
cinoma	 –	ductal carcinoma in situ	 (DCIS)	while	 it	 is	 still	
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a	non-palpable	lesion,	less	than	1	cm	in	size,	results	in	the	
100%	 cure	 rate	 [3,	4].	 The	 detection	 of	 grade	 1	 invasive	
carcinoma	(IC)	(T1,N0,M0	according	to	the	TNM	classifica-
tion),	i.e.	a	tumor	up	to	2	cm	in	size,	offers	a	90%	chance	for	
a	complete	recovery	[5].
The	 symptoms	 of	 preclinical	 carcinoma	 that	 are	 usually	
seen	 in	 imaging	 studies	 include	microcalcifications	 (42%),	
small	 nodules	 (39%)	 and	 abnormalities	 of	 the	mammary	
gland	architecture	(19%).	Today,	in	the	case	of	these	patho-
logical	lesions	(i.e.	small	and	non-palpable),	there	is	no	suf-
ficiently	 effective	method	 of	 biopsy	 verification	 available	
other	than	surgical	intervention	[6].	
Fine	 needle	 aspiration	 biopsy	 (FNAB)	 is	 characterized	 by	
a	 relatively	 low	 sensitivity,	 even	 as	 low	as	 53%	 [7];	 addi-
tionally	 it	 does	not	 afford	 for	 determining	 the	 grade	 of	 a	
tumor.	Core	needle	biopsy	(CNB),	although	its	effectiveness	
is	higher	when	 compared	 to	FNAB,	yields	 results	 that	 are	
closely	dependent	on	the	volume	of	collected	tissue;	during	
a	 standard	biopsy	 this	necessitates	 the	breast	 to	be	punc-
tured	 several	 times	with	a	 core	needle	 (14-11	Ga)	 [6].	The	
sensitivity	 of	 CNB,	 depending	 on	 the	 clinical	 experience,	
ranges	from	53	to	94%	[8].	
A	method	that	so	far	has	been	yielding	the	best	results,	i.e.	
one	that	has	the	sensitivity	and	specificity	that	approximate	
100%,	 is	 open	 surgical	biopsy.	 In	 the	 case	of	non-palpable	
lesions,	it	is	performed	with	a	prior	insertion	of	a	location	
needle	under	ultrasonographic	or	mammographic	guidance.	
The	procedure	is	performed	in	the	operating	room	and	thus	
is	 relatively	 expensive.	 In	 addition	 it	 is	 always	 associated	
with	 breast	 deformation	 (a	 tumorectomy	 scar),	 a	 risk	 of	
infection	and	at	least	1–3	days	absence	from	work.	
In	view	of	 the	above	considerations,	 in	 the	 last	 few	years	
the	key	issue	has	been	the	development	of	a	new,	relatively	
non-invasive	method	 allowing	 for	 a	 reliable	 detection	 of	
preclinical	breast	cancers.	
The	aim	of	the	present	 investigations	 is	 the	assessment	of	
the	 effectiveness	 of	 core	needle	 vacuum-assisted	biopsy	 –	
Mammotome	biopsy	(MB),	guided	either	by	ultrasonography	
or	digital	mammography,	in	differentiating	suspect	preclini-
cal	breast	lesions.	
Material and methods
The	material	 consisted	 of	 847	 women	 aged	 32–72	 years	
of	 life	 (mean	age,	56	years)	 seen	at	 the	Regional	Center	of	
Early	Diagnostic	 and	Therapeutic	Management	 of	 Breast	
Diseases,	whose	were	 referred	 to	MB.	 All	 these	 patients	
had	 been	 subjected	 to	 clinical	 examinations,	 compara-
tive	mammography	and	ultrasound.	When	mammography	
detected	 microcalcifications	 and	 structural	 distortions,	
magnified	spot	images	were	additionally	obtained.	
All	the	thus	revealed	lesions	were	undetectable	by	physical	
examination	and	their	size	at	the	longest	dimension	did	not	
exceed	1	cm.	
Depending	on	the	imaging	method	that	allowed	for	a	more	
precise	 visualization	 of	 the	 suspect	 lesion,	 the	 patients	
were	divided	into	two	groups:	
–		Group	1	consisted	of	349	females	referred	to	digital	mam-
mography-guided	MB.	Of	this	number,	the	procedure	was	
ultimately	 employed	 in	 323	 patients	 (93%).	 In	 26	 cases	
(7%),	 the	 biopsy	 could	 not	 have	 been	 accomplished	 for	
the	 following	reasons:	 the	 location	of	 the	 lesion	was	 too	
close	to	the	digital	detector,	what	posed	a	risk	of	hitting	
its	surface	with	the	needle	 (10	patients),	 the	 lesions	was	
situated	too	superficially	with	respect	to	the	skin	surface,	
what	 rendered	 the	 complete	 introduction	 of	 the	 biopsy	
chamber	 into	 the	breast	 impossible	 (14	women),	 and	no	
consent	 for	MB	was	 given	 (2	 females)	 (Table	 1).	 In	 this	
group,	 pathological	 lesions	where	 biopsy	was	 indicated	
included:	 suspicious	microcalcifications	 (N	=	257;	 79%),	
structural	 distortions	 in	 the	 form	of	 asymmetric	 abnor-
malities	of	breast	architecture	(N	=	42,	13%)	and	masses	
with	 irregular	 shapes,	 not	 observed	 in	 previously	 per-
formed	ultrasonography	(N	=	24,	8%).	
–		Group	 2	 included	 498	 patients,	 who	 were	 referred	 to	
ultrasonography-guided	 MB.	 Of	 this	 number,	 biop-
sies	were	 ultimately	 performed	 in	 496	women	 (99.6%).	
The	 remaining	 two	 females	 (0.4%)	 refused	 their	 consent	
(Table	1).	
–		All	the	lesions	in	this	group	were	classified	by	USG	as	solid,	
irregular	in	shape	masses	with	retrotumoral	shadowing.	
In	Group	1	eight	patients	(2.5%)	(Table	1),	repeated	MB	pro-
cedures	were	performed	due	to	bleeding	that	rendered	con-
tinuing	 the	biopsy	 impossible	 (5	 cases)	 and	not	 completed	
biopsy	 in	three	patients	 (follow-up	mammography	demon-
strated	 that	 the	major	 part	 of	 the	 lesion	was	 left	 intact,	
while	histopathology	showed	the	 lesion	to	be	non-atypical	
ductal	hyperplasia	(NADH)).
In	Group	 2,	 rebiopsies	were	 performed	 in	 three	 patients	
(0.6%)	 (Table	 1)	 due	 to	 bleeding	not	 allowing	 for	 continu-
ing	 the	 procedure	 (N	 =	 2)	 and	 not	 completed	 biopsy	 in	
one	 female	 (follow-up	ultrasonography	demonstrated	 that	
a	major	 part	 of	 the	 lesion	persisted,	while	histopathology	
confirmed	the	lesion	as	NADH).	
Table 1.  Number of patients subjected to mammotome biopsy procedures.
Tabela 1.  Liczba pacjentów skierowanych do biopsji mammotomicznej.
No. of patients referred to MB No. of finally performed MB No. of not performed MB No. of rebiopses
GROUP 1 349 (100%) 323 (93%) 26 (7%) 8 (2.5%)
GROUP 2 498 (100%) 496 (99.6%) 2 (0.4%) 3 (0.6%)
TOTAL 847 (100%) 819 (97%) 28 (3%) 11 (1.3%)
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Digital	 mammography-guided	 MB	 was	 performed	 using	
a	unit	 composed	 of	 two	parts:	 a	 stereotactic	 biopsy	 table	
with	a	CCD	camera	and	a	Mammotome	biopsy	device.
The	 construction	 of	 the	 table	 necessitated	 placing	 the	
patient	 in	 the	 prone	 position,	 with	 the	 biopsied	 breast	
protruding	below	 the	 tabletop	 through	 a	 special	 opening.	
Below	the	tabletop	there	was	a	mobile	L	arm	equipped	with	
a	CCD	camera,	digital	detector,	a	compression	paddle	with	
a	window	 (5x5	cm	 in	 size)	 corresponding	 to	 the	examined	
part	 of	 the	breast,	 and	 a	 computer-controlled	 attachment	
with	 the	holder	 for	mounting	 a	mammotome	device	with	
the	 biopsy	 needle.	 The	method	 of	 stereotaxy	 is	 based	 on	
determining	 three	 coordinates	 illustrating	 the	 location	 of	
the	lesion	(which	is	positioned	centrally	in	the	compression	
paddle’s	window)	 from	 three	 exposures	 –	 one	 scout	 view	
(Fig.	1),	 performed	 along	 the	 long	 axis	 of	 the	L	 arm	 –	 0o,	
and	 two	 (the	 so-called	 stereo	 views)	 taken	with	 the	 arm	
with	 its	CCD	camera	deflected	 at	 the	 same	15o	 angle,	 but	
in	 two	opposite	 directions	 (+15o	 and	 –15o).	 Subsequently,	
the	operator	used	a	mobile	mark	to	select	the	same	target	
point	 in	 the	 two	 resultant	 stereotactic	 views	 seen	 on	 the	
monitor,	as	well	as	the	previously	programmed	needle	type.	
Since	 both	 the	 length	 of	 the	needle	 and	 the	 length	 of	 the	
path	leading	to	the	target	constituted	parameters	that	were	
Figure 1 a,b,c.   Pleomorphic clustered microcalcification (ductal 
carcinoma in situ) a. scout view b. scout view with 
edge enhancement option c. scout view with edge 
enhancement and zoom options.
Rycina 1 a,b,c.   Skupisko pleomorficznych mikrozwapnień (ductal 
carcinoma in situ) a. zdjecie „na wprost” b. zdjęcie 
„na wprost” po zastosowaniu opcji „wzmocnienia 
krawędzi” c. zdjęcie „na wprost” po zastosowaniu 
opcji „wzmocnienia krawędzi” oraz dodatkowego 
powiększenia (zoom).
A
B C
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encoded	by	the	unit	as	the	safety	margin,	the	computer	cal-
culated	the	values	of	 the	x,	y	and	z	coordinates	and	auto-
matically	signaled	the	possible	risk	of	puncturing	the	breast	
through	 and	hitting	 the	 detector	with	 the	 needle	 (Fig.	2).	
The	 needle	 itself	 was	 blind-ended	 and	 collected	 tissue	
specimens	through	a	biopsy	window,	which	was	connected	
with	a	vacuum	suction	device.	In	addition,	the	needle	was	
equipped	with	a	mobile	co-axial	core	with	a	cutting	section	
adapted	 to	 collecting	 tissue	 specimens	 for	 histopathology.	
In	 our	material,	 one	11	Ga	needle	 served	 to	 collect	 16–30	
cylindrical	tissue	specimens,	what	corresponded	to	collect-
ing	the	total	of	50	to	150	mg	of	the	tissue.	
All	the	computer-determined	coordinates	were	subsequent-
ly	transmitted	to	the	stereotactic	attachment	equipped	with	
a	biopsy	needle	and	the	attachment	was	automatically	set	
to	target	site.	
During	 the	 entire	 procedure,	 both	 before	 and	 after	 intro-
ducing	the	needle	into	the	breast,	the	position	of	the	cutting	
section	was	monitored	via	serial	stereo	images	(Fig.	3–4).	
Following	 the	 connection	 of	 the	 vacuum	 device	 to	 the	
biopsy	needle,	the	needle	was	introduced	manually	into	the	
breast,	and	then	a	spring	pull	mechanism	were	used,	reach-
ing	the	previously	determined	depth.	Immediately	prior	to	
introducing	the	needle	into	the	breast,	the	area	of	the	skin	
in	front	of	the	needle	was	sterilized	and	an	approximately	
3–4	mm	 long	 incision	was	made.	The	collected	cylindrical	
specimens	were	 placed	 in	 special	 X-ray-transparent	 cas-
settes.	 Each	 time	 prior	 to	withdrawing	 the	mammotome	
needle	from	the	breast,	a	titanium	marker	was	introduced	
into	 the	biopsy	 site	 through	 the	biopsy	 canal	 to	 allow	 for	
future	localization	of	the	site.	A	single	X-ray	exposure	of	the	
cassettes	made	it	possible	to	confirm	the	presence	of	micro-
calcifications	 in	 the	 bioptates	 (Fig.	5–6).	 Confirmation	 of	
sample	collection	from	a	lesion	that	did	not	contain	micro-
calcifications	was	obtained	by	visualizing	a	density	focus	at	
the	biopsy	site	in	a	follow-up	mammographic	picture	taken	
immediately	 upon	withdrawing	 the	 biopsy	needle,	which	
corresponded	to	local	bleeding	(Fig.	7).	Due	to	the	employed	
vacuum-assisted	device,	 a	 single	needle	 insertion	 allowed	
for	 collecting	 samples	within	 the	 radius	of	1.5–2	 cm	 from	
the	puncture	 axis.	After	 the	procedure,	 the	patients	were	
under	observation	for	3	to	4	hours.	
Digital	technology	allowed	for	taking	advantage	of	all	oppor-
tunities	 offered	 by	 computerized	 image	 processing	 (post-
processing),	 such	 as	 smooth	 regulation	 of	 contrast,	 focus	
and	negative-positive	 opposition,	 additional	 edge	 enhance-
ment,	measurement	 taking,	 enlarging	 selected	 image	 frag-
ments	and	finally	storing	data	in	the	electronic	format.	
An	 ultrasound-guided	 MB	 unit	 consisted	 of	 the	 above	
described	 biopsy	 unit	 connected	 with	 a	 vacuum	 device.	
The	ultrasonograph	was	not	connected	to	the	unit	and	con-
stituted	a	separate	entity	–	in	the	present	investigations	it	
was	a	Hitachi	EUB	450	with	a	7.5	MHz	linear	probe.	
Figure 2.  Microcalcification cluster in the two stereotactic views, 
already marked, with calculation of x, y and z coordinates 
of the target. 
Rycina 2.  Dwa zdjęcia stereotaktyczne z zaznaczonym skupiskiem 
mikrozwapnień z wyliczonymi współrzędnymi celu x, y, z . 
Figure 3.  Two control stereotactic views after manually introduced 
mammotome needle into the breast.
Rycina 3.  Dwa kontrolne zdjęcia stereotaktyczne wykonane po 
„ręcznym” wprowadzeniu w pierś igły mammotomicznej.
Figure 4.  Next two control stereotactic views after using spring pull 
mechanism. On both views, marks are located within 
biopsy window (arrows) which means that needle reached 
previously determined target. 
Rycina 4.  Kolejne dwa kontrolne zdjęcia stereotaktyczne wykonane 
po zwolnieniu naciągu sprężynowego. Na obu zdjęciach 
w rzucie okienek biopsyjnych widoczne markery 
co oznacza, że igła znajduje się dokładnie w wyliczonej 
wcześniej lokalizacji.  
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In	 addition	 to	 examining	 the	 biopsy	 materials	 in	 the	
form	 of	 serial,	 paraffin-embedded	 sections,	 they	 were	
also	 analyzed	 by	 immunohistochemistry	 and	 cytom-
etry	 to	 establish	 a	 firm	 diagnosis	 and	 –	 in	 the	 case	
breast	 cancer	was	detected	 –	 to	 precisely	 determine	 the	
grade.
In	 each	 case	 of	 carcinoma	 detection,	 the	 patient	 was	
referred	 to	 surgery.	 In	benign	 lesions	 (diagnosed	based	on	
post-MB	 histopathology),	 the	 patients	 were	 included	 in	
long-term	follow-up	using	imaging	studies.
Results
Based	 on	 post-MB	 histopathology	 results,	 the	 follow-
ing	 conditions	were	 detected	 in	Group	 1:	 21	 (6.5%)	 cases	
of	 invasive	 ductal	 carcinoma	 (IDC),	 28	 (8.7%)	 instances	
of	DCIS	 and	34	 (10.5%)	 cases	 of	 atypical	 ductal	 hyperpla-
sia	 (ADH).	The	 remaining	240	patients	 (74.3%)	had	benign	
lesions	(Table	2).	
Histopathology	 performed	 after	MB	 revealed	 in	 Group	 2	
a	 total	of	42	 (8.5%)	 IDC,	3	 (0.6%)	cases	of	DCIS	and	5	 (1%)	
cases	 of	 ADH.	 The	 remaining	 446	 women	 (89.9%)	 were	
demonstrated	to	have	benign	lesions	(Table	2).
Figure 5 a,b,c.   Verification images directly after biopsy procedure. 
a, b. 2 control stereotactic views showing biopsy 
site with titanium marker (arrows). There is no any 
more microcalcifications seen c. Single x-ray of the 
cassettes with biopsy speciment confirm presence 
of microcalcification (arrow).
Rycina 5 a,b,c.   Zdjęcia kontrolne zrobione bezpośrednio po biopsji 
a, b. 2 zdjęcia stereotaktyczne loży po zmianie 
z widocznym znacznikiem tytanowym. Nie uwidacznia 
się mikrozwapnień (strzałka) c. Pojedyncze zdjęcie 
kasetki zawierającej pobrane próbki, z widocznym 
usuniętym skupiskiem mikrozwapnień (strzałka). 
A B
C
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Figure 6 a,b.   Linear branching calcifications (invasive ductal carcinoma) a. Stereotactic view with the lesion before mammotome biopsy (zoom 
option) b. Control stereotactic view with the biopsy site after procedure (zoom option).
Rycina 6 a,b.   Linijne, rozgałęziające się mikrozwapnienia (invasive ductal carcinoma) a. Zdjęcia stereotaktyczne zmiany wykonane przed biopsją 
mammotomiczną (włączona opcja dodatkowego powiększenia) b. Kontrolne zdjęcia stereotaktyczne loży wykonane po biopsji 
mammotomicznej (włączona opcja dodatkowego powiększenia).
Figure 7 a,b.   Non-palpable mass with irregular shape and spiculated margin, 8x7 mm in dimentions, not visible in US (invasive ductal  
carcinoma) a. Scout view with the lesion before mammotome biopsy b. Control scout view with the  biopsy site after  
procedure.
Rycina 7 a,b.   Niepalpacyjne, spikularnego kształtu zacienienie, o nieregularnym obrysie, o wym. ok. 8x7 mm, niewidzialne w badaniu USG (invasive 
ductal carcinoma) a. „Zdjęcie na wprost” zmiany wykonane przed biopsją mammotomiczną  b. Kontrolne „zdjęcie na wprost” loży 
wykonane po biopsji mammotomicznej.
A B
A B
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Of	the	total	number	of	819	females	(i.e.	97%	of	all	patients	
included	 into	 the	 investigation),	 rebiopsies	 were	 per-
formed	 in	 11	 (1.3%)	women.	The	 criterion	 for	 referring	
patients	to	a	repeated	biopsy	was	the	simultaneous	occur-
rence	 of	 three	phenomena:	 persistent	 suspicious	 charac-
ter	of	the	detected	pathological	lesion,	NADH	detected	in	
histopathology	 after	 the	 first	 mammotome	 biopsy,	 and	
a	 large	 fragment	 of	 the	 lesion	 left	 in	 situ.	Of	 11	 rebiop-
sies,	histopathological	qualification	was	changed	in	three	
patients	(27%).
In	Group	1,	a	repeated	MB	led	to	changing	the	histopathol-
ogy	result	in	two	cases.	In	one	patient	ADH	was	diagnosed,	
while	another	was	found	to	have	DCIS.
In	 Group	 2,	 the	 rebiopsy	 changed	 the	 histopathology	
assessment	in	one	patient,	who	was	ultimately	diagnosed	
as	ADH.	
To	 control	biopsy	 site	bleeding,	 all	 the	patients	were	 sub-
jected	to	follow-up	ultrasound	performed	1	and	7	days	after	
the	biopsy.	Fifty-eight	(7%)	women	developed	hematomas	of	
more	 than	1	 cm	 in	 diameter.	Of	 this	 number,	 in	 54	 cases	
the	 hematomas	 did	 not	 exceed	 2	 cm	 and	were	 absorbed	
spontaneously;	 only	 in	 four	patients	 (0.5%)	was	 the	diam-
eter	 larger	 than	 2	 cm	 and	 the	 hematomas	 needed	 to	 be	
aspirated.
In	eight	patients	(0.9%),	bleeding	occurred	in	the	course	of	
MB	 that	 prevented	 the	 continuation	 of	 the	procedure.	All	
these	patients	were	rebiopsied.
Fifteen	women	of	Group	1	(1.8%)	subjected	to	digital	mam-
mography-guided	MB,	 complained	 of	 cervical	 spine	 trou-
bles	associated	with	the	position	they	had	to	assume	on	the	
biopsy	table.	
As	 the	 reference	 study	 the	 authors	 adopted	 the	 surgical	
procedure	performed	 in	 all	 the	women,	 in	whom	MB	had	
detected	a	cancer	or	ADH.	Patients,	in	whom	post-MB	his-
topathology	indicated	an	unmistakable	benign	character	of	
the	biopsied	lesion	were	closely	followed-up	using	imaging	
techniques.	To-date,	none	of	them	has	revealed	the	appear-
ance	of	new,	suspect	lesions	within	the	biopsy	site.	
In	Group	1,	histopathological	examinations	of	postoperative	
preparations	revealed	24	(7.4%)	cases	of	IDC,	26	(8.1%)	DCIS	
and	33	(10.2%)	cases	of	ADH	(Table	3).	
Postoperative	histopathology	showed	in	Group	2	a	total	of	
43	 (8.7%)	 IDC,	 2	 (0.4%)	 cases	 of	DCIS	 and	 5	 (1%)	 cases	 of	
ADH	(Table	3).
When	we	compare	post-MB	histopathological	 results	with	
reference	 postoperative	 histopathology	 findings,	we	 note	
that	the	sensitivity	of	the	method	in	detecting	breast	cancer	
in	Group	1	was	98%	and	the	specificity	amounted	to	100%.	
In	Group	2	 both	 the	 sensitivity	 and	 specificity	 amounted	
to	100%.	In	general,	the	sensitivity	of	MB	in	detecting	pre-
clinical	breast	cancers	measuring	less	than	1	cm	was	98.9%	
and	the	specificity	was	100%	(Table	4).	The	positive	result	
prediction	 value	 (PPV)	 for	 Group	 1	was	 100%,	while	 the	
corresponding	value	for	negative	results	(NPV)	amounted	to	
99.7%.	In	Group	2,	the	same	indices	were	PPV	–	100%	and	
NPV	 -	 100%.	The	 combined	value	 of	 PPV	 for	MB	equaled	
100%,	while	NPV	was	99.8%	(Table	4).	The	reliability	index	
BM	LR+	was	98.9.	
Discussion
The	methods	 of	 percutaneous	 biopsy	 employed	 today	 in	
the	 diagnostic	 management	 of	 preclinical	 carcinomas,	
despite	their	widespread	use,	are	not	characterized	by	high	
effectiveness.	
Table 2.  Post-mammotome biopsy histopathological findings.
Tabela 2.  Wyniki badań histopatologicznych po biopsji mammotomicznej. 
No. of IDC No. of DCIS No. of ADH No. of benign lesions
GROUP 1 21 (6.5%) 28 (8.7%) 34 (10.5%) 240 (74.3%)
GROUP 2 42 (8.5%) 3 (0.6%) 5 (1.0%) 446 (89.9%)
TOTAL 63/819 (7.7%) 31/819 (3.8%) 39/819 (4.8%) 686/819 (83.7%)
Table 4.  Sensitivity, specificity, and prediction coefficients for mammotome biopsy in detection of preclinical neoplastic lesions.
Tabela 4.  Czułość, swoistość oraz wartości predykcji biopsji mammotomicznej w wykrywaniu przedklinicznych zmian nowotworowych piersi.
SENSITIVITY SPECIFICITY PPV NPV 
GROUP 1 98% 100% 100% 99.7%
GROUP 2 100% 100% 100% 100%
TOTAL 98.9% 100% 100% 99.8%
Table 3.  Postoperative histopathological findings.
Tabela 3.  Wyniki badań histopatologicznych po zabiegu operacyjnym.
No. of IDC No. of DCIS No. of ADH
GROUP 1 24 (7.4%) 26 (8.1%) 33 (10.2%)
GROUP 2 43 (8.7%) 2 (0.4%) 5 (1.0%)
TOTAL 67/819 (8.2%) 28/819 (3.4%) 38/819 (4.6%)
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We	must	 agreed	 that	FNAB	–	 in	view	of	 the	 fact	 that	 only	
cellular	material	is	collected	–	has	a	low	sensitivity,	ranging	
from	 54	 to	 78%,	 which,	 nevertheless,	 increases	 with	 the	
growing	size	of	 the	biopsied	 lesion	 [9].	 In	addition,	what	 is	
emphasised	by	cytologist,	FNAB	is	not	a	method	that	would	
be	capable	of	assessing	the	grade	of	invasive	carcinoma	[10].	
The	 sensitivity	 of	CNB,	 similarly	 as	 in	 the	 case	 of	 FNAB,	
increases	with	 the	 increase	 of	 the	biopsied	 lesions.	 In	 the	
case	 of	 all	 non-palpable	 lesions,	 two	 or	 three	 punctures	
are	necessary	 for	 the	 sensitivity	 of	CNB	 to	 go	beyond	 the	
threshold	value	of	90%	[11,	12,	13,	14].
The	 employed	 today	 open	 surgical	 biopsy	 requires	 the	
lesion	to	be	identified	with	the	help	of	a	localization	needle	
and	 then	 the	 procedure	 has	 to	 be	 performed	 in	 the	 ope-
rating	room	setting.	It	is	also	associated	with	complications	
resulting	 from	general	 anesthesia,	 inflammatory	 process-
es,	 hematomas	 and	 always	with	 breast-deforming	 scars.	
One	needs	also	to	bear	in	mind	the	fact	that	when	a	small	
lesion	 is	 operated	 on,	 often	 intraoperative	 histopathology	
(in	 a	 frozen	preparation)	 is	 not	 done	because	 its	 result	 is	
often	 falsely	negative	and	at	 the	 same	 time	 the	 technique	
rules	out	any	verification	of	the	same	preparation	using	the	
paraffin	method.	The	latter,	if	the	result	is	positive,	heralds	
at	least	two	surgical	procedures	[15].	
In	 our	 experience,	 in	MB	 thanks	 to	 the	use	of	vacuum	and	
the	multidirectional	method	 of	 biopsy	 specimen	 collection,	
already	 the	 first	 introduction	 of	 the	 mammotome	 needle	
to	 the	 area	where	 the	 suspect	 lesion	 is	 situated	 allows	 for	
performing	a	successful	biopsy.	As	accent	by	others	this	not	
only	shortens	the	duration	of	the	procedure,	but	is	also	less	
painful	and	stressful	for	the	patient.	Additionally,	the	use	of	
imaging	techniques	in	evaluating	the	biopsy	site	both	in	the	
course	of	the	procedure	and	immediately	afterwards	gives	an	
opportunity	 –	unrivalled	by	 other	methods	 –	 of	 visualizing	
and	assessing	the	effectiveness	of	the	biopsy	[13,	14].	
The	fact	that	MB	visualized	almost	unchanged	contours	of	
the	 biopsied	 lesions	 combined	with	 a	 low	number	 of	 tis-
sue	 samples	 collected	 allowed	 for	 reaching	 a	 decision	 to	
rebiopsy	 the	 patient.	 In	 consequence,	 in	 three	 cases	 the	
final	diagnosis	was	changed.	Yet	we	should	stress	here	that	
the	total	percentage	of	rebiopsies	required	 in	our	material	
was	only	1.7%.	
A	 comparison	 of	 histopathological	 findings	 obtained	 after	
MB	and	after	the	surgery	showed	only	relatively	slight	dif-
ferences.	 Of	 323	women	 belonging	 to	Group	 1,	 the	 diag-
nosis	was	changed	 in	 three	cases	 (0.9%),	while	 in	Group	2	
such	 a	change	 occurred	 solely	 in	 one	patient	 (0.2%).	Only	
the	 grade	 of	 the	 tumor	was	 underestimated	 in	 all	 these	
patients.	The	errors	of	underdiagnosis	following	MB	did	not	
affect	 the	 diagnostic	 and	 therapeutic	management,	 since	
the	differences	 involved	 solely	ADH-type	 lesions	 or	 carci-
nomas,	which	anyway	required	surgical	treatment.	
The	achieved	by	us	98.9%	sensitivity	and	100%	specificity	of	
MB	in	detecting	preclinical	breast	cancers	is	very	high	and	
comparable	to	the	results	obtained	by	others	in	open	surgi-
cal	biopsy,	the	latter	being	presently	regarded	as	“the	golden	
standard”	 [12,	16,	17].	 The	 differences	 seen	 in	 the	 results	
obtained	in	both	groups	have	their	origin	in	the	very	biopsy	
technique	 employed.	 Ultrasound-guided	 MB	 provides	 an	
opportunity	of	correcting	 the	position	of	 the	needle	during	
the	procedure,	while	the	puncture	site	remains	unchanged,	
since	the	biopsy	unit	is	stabilized	by	the	hand	of	the	opera-
tor.	This	 allows	 for	 a	more	 “elastic”	 approach	 to	 the	biop-
sied	 lesion	without	 the	need	 of	 additionally	 damaging	 the	
skin.	 In	digital	mammography-guided	MB,	 each	 correction	
of	 the	positioning	of	 the	needle,	which	 is	 stabilized	by	 the	
holding	device	on	the	L	arm,	requires	–	apart	from	forward	
and	backward	motions	 –	 the	needle	 to	 be	withdrawn	and	
another	target	to	be	adopted,	what	in	the	majority	of	cases	
is	associated	with	the	computer	determining	another	punc-
ture	site.	This	 is	why	problems	associated	with	unsuccess-
ful	 biopsing	 of	 a	 lesion	were	 encountered	 only	 in	Group	1	
and	originated	mainly	from	our	 lack	of	experience	and	our	
desire	to	spare	the	patient	from	additional	stress	associated	
with	another	insertion	of	the	biopsy	needle.	
The	 high	 values	 of	 the	 PPV	 and	NPV	 coefficients	 in	MB	
indicate	 that	 the	method	allows	 for	 a	 reliable	 differentia-
tion	between	malignant	and	benign	lesions.	
Similarly	as	open	biopsy,	MB	allows	for	obtaining	material	
for	histopathology,	but	the	latter	is	at	the	same	time	a	pro-
cedure	of	low	degree	of	invasiveness	and	may	be	performed	
under	local	anesthesia	in	an	outpatient	setting.	
The	risk	of	complications	in	mammotomy	is	low	and	includes	
bleeding	from	the	puncture	site,	subcutaneous	hemorrhages	
and	petechiae	 that	 are	 resorbed	within	 one	week	 after	 the	
procedure.	In	our	material	only	four	patients	developed	diffi-
cult	resorbable	hematomas,	which	required	aspiration.	They	
might	have	been	caused	by	the	fact	 that	those	patients	had	
failed	to	discontinue	their	anticoagulants.	
The	procedure	of	MB	leaves	only	a	several	millimeter-long	
scar,	 which	 disappears	 after	 3–4	 months,	 thus	 ensuring	
a	very	good	cosmetic	effect.	
The	present	results	reliably	confirm	the	very	high	effective-
ness	 of	 MB	 in	 differentiating	 preclinical	 carcinomas	 that	
require	unequivocal	verification.	Our	ability	 to	perform	MB	
both	under	 the	 guidance	 of	 a	mammography	 or	 ultrasono-
graphy	allows	for	performing	the	procedure	regardless	of	the	
character	of	the	lesion	and	the	type	of	breast	structure,	what	
emphasizes	the	complementary	character	of	both	MB	types.	
Conclusions
1.		Mammotome	 biopsy	 is	 an	 alternative	method	 to	 open	
surgical	 biopsy	 in	differentiating	preclinical	 breast	 can-
cers	of	less	than	1cm	in	size.
2.		MB	 is	 a	method	of	 low	 invasiveness,	well	 tolerated	by	 the	
patients	and	associated	with	a	minimal	risk	of	complications.	
3.		Depending	 on	 the	 indications,	 MB	 may	 be	 performed	
either	under	ultrasonography	or	mammography	guidance.
4.		MB	 is	 a	 procedure	 performed	 in	 an	 outpatient	 setting	
that	 leaves	 a	 minimal	 scar,	 which	 does	 not	 deform	
the	breast.
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